Trial Profile
A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) Compared With the Existing COPD Maintenance Therapy Alone in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Oct 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms SLS COPD
- Sponsors GlaxoSmithKline; GSK
- 01 May 2022 According to a Form 6-K, 2022, company SEC filing, GlaxoSmithKline has changed its name to GSK.
- 11 Jan 2020 Results published in the Advances in Therapy
- 01 Feb 2019 Results assessing fluticasone furoate/vilanterol effectiveness and safety in predefined patient subgroups, published in the Respiratory Medicine.